Annual report
3341.TEDINET S100W6B8
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥360.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥340.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥313.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥299.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥279.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥6.2bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥9.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥6.9bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥9.4bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.7bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.9bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.1bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.5bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥197.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥195.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥185.3bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥178.8bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥186.3bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥138.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥136.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥56.5bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥52.9bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥49.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥27.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥32.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥8.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥19.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥9.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥713m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥17.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥46.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.92 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.56 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.01 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,978.13 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,950.44 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,888.17 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,763.34 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,663.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 30.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.5% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.5% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 6,063 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 5,864 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,689 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 5,552 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,221 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥315.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥298.0bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥275.3bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥259.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥233.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥7.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.6bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥3.0bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥3.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥157.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥155.7bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥148.3bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥140.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥145.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥112.9bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥111.9bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥44.3bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥43.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥41.5bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥39.2bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥37.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥19.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥18.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥43.94 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.76 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.35 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.25 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.69 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥25 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,482.24 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,462.94 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,388.25 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,308.05 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,255.8 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 28.2% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 31,048,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 31,048,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,798 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 4,642 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 4,587 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 4,458 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,034 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 70
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥788m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥7.5bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥6.6bn |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Dispensing Pharmacy Businessreportable segment | employees | at 2025-03-31 | 4752 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥322.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥322.0bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2025-03-31 | ¥118.4bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥13.4bn |
| Medical Professional Staffing And Placement Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥119m |
| Medical Professional Staffing And Placement Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥131m |
| Medical Professional Staffing And Placement Businessreportable segment | employees | at 2025-03-31 | 321 pure |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.4bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.2bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥185m |
| Medical Professional Staffing And Placement Businessreportable segment | segment assets | at 2025-03-31 | ¥5.4bn |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥937m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2.3bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | employees | at 2025-03-31 | 838 pure |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥40.2bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥27.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12.8bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment assets | at 2025-03-31 | ¥70.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥630m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥9.1bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥373.5bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥360.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥13.0bn |
| —segment total | segment assets | at 2025-03-31 | ¥194.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥780m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥12.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥12.9bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥3.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥7.2bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥8.9bn |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥302.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥302.8bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥115.7bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥15.2bn |
| Medical Professional Staffing And Placement Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥83m |
| Medical Professional Staffing And Placement Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥147m |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.9bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥111m |
| Medical Professional Staffing And Placement Businessreportable segment | segment assets | at 2024-03-31 | ¥5.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥937m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥40.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥27.6bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12.8bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment assets | at 2024-03-31 | ¥71.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥250m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥6.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥353.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥340.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12.9bn |
| —segment total | segment assets | at 2024-03-31 | ¥191.7bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | employees | at 2025-03-31 | 4646 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,575
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 4642 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 4798 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 714 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 735 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 728 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 694 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 673 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.094 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.834 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.744 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.018 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.976 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.421 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.450 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.534 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 2.168 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.134 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E05422-000DispensingPharmacyBusinessReportableSegmentMember | 4752 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E05422-000DispensingPharmacyBusinessReportableSegmentMember | 667 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentMember | 838 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentMember | 41 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentMember | 321 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentMember | 16 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 152 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 24 | |
| Number of employees | CurrentYearInstant | 6063 | |
| Average number of temporary workers | CurrentYearInstant | 748 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 4798 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 673 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 35.5 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7.83 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5713000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05422-000DispensingPharmacyBusinessReportableSegmentMember | 4646 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05422-000DispensingPharmacyBusinessReportableSegmentMember | 648 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 152 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 24 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 4798 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 673 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.152 | |
| All employees calculated based on provisions of article714 item2 of ordinance for enforcement of act on childcare leave caregiver leave and other measures for the welfare of workers caring for children or other family members ratio of male employees taking childcare leave metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.864 | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.653 | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.675 | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.614 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.128 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.714 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.785 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.795 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.790 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.097 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 1.000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |